Apt-3 aptamer against C promoter binding factor 1 (CBF1) Aptamer Details
ID# 8115
Structure
Chemistry
DNA
Target
C promoter binding factor 1 (CBF1)
Category
Protein
Affinity (Kd)
34 nM
Length
73
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5'-dApdTpdApdGpdGpdApdGpdTpdCpdGpdApdCpdCpdGpdApdCpdCpdApdGpdApdCpdCpdApdApdCpdCpdCpdTpdApdCpdGpdCpdGpdTpdApdCpdCpdApdApdCpdCpdApdGpdApdTpdGpdApdCpdCpdTpdApdCpdGpdTpdGpdCpdGpdTpdCpdTpdApdCpdApdTpdCpdTpdApdGpdApdCpdTpdCp -3'
Molecular Weight: 22004.3
Extinction Coefficient: 693600
Binding Conditions / Buffer
100 mM Tris-HCl (pH 8.0), 100 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.1% Tween 20, 1 mg/mL BSA
Binding Temp: 22°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Tezuka-Kagajo, Mari et al. “Development of Human CBF1-Targeting Single-Stranded DNA Aptamers with Antiangiogenic Activity In Vitro.” Nucleic acid therapeutics vol. 30,6 (2020): 365-378. doi:10.1089/nat.2020.0875
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
